Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 7 |
List of Tables | 7 | 1 |
List of Figures | 8 | 1 |
Introduction | 9 | 1 |
Global Markets Direct Report Coverage | 9 | 1 |
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview | 10 | 1 |
Therapeutics Development | 11 | 2 |
Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview | 11 | 1 |
Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Comparative Analysis | 12 | 1 |
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics under Development by Companies | 13 | 2 |
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Pipeline Products Glance | 15 | 4 |
Late Stage Products | 15 | 1 |
Clinical Stage Products | 16 | 1 |
Early Stage Products | 17 | 1 |
Unknown Stage Products | 18 | 1 |
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Products under Development by Companies | 19 | 2 |
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Companies Involved in Therapeutics Development | 21 | 26 |
AnGes MG, Inc. | 21 | 1 |
AstraZeneca Plc | 22 | 1 |
Athera Biotechnologies AB | 23 | 1 |
Athersys, Inc. | 24 | 1 |
Bayer AG | 25 | 1 |
Betagenon AB | 26 | 1 |
BiogenCell Ltd. | 27 | 1 |
CardioVascular BioTherapeutics, Inc. | 28 | 1 |
Celgene Corporation | 29 | 1 |
Diffusion Pharmaceuticals Inc | 30 | 1 |
Hemostemix Ltd | 31 | 1 |
ID Pharma Co., Ltd. | 32 | 1 |
Juventas Therapeutics, Inc. | 33 | 1 |
LipimetiX Development Inc | 34 | 1 |
miRagen Therapeutics, Inc. | 35 | 1 |
Nuo Therapeutics, Inc. | 36 | 1 |
Proteon Therapeutics, Inc. | 37 | 1 |
Recardio GmbH | 38 | 1 |
Resverlogix Corp. | 39 | 1 |
Sigma-Tau S.p.A. | 40 | 1 |
Stemedica Cell Technologies, Inc. | 41 | 1 |
Symic Biomedical, Inc. | 42 | 1 |
Theravasc, Inc. | 43 | 1 |
VESSL Therapeutics Ltd | 44 | 1 |
ViroMed Co Ltd | 45 | 1 |
Yuyu Pharma, Inc. | 46 | 1 |
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Assessment | 47 | 9 |
Assessment by Monotherapy Products | 47 | 1 |
Assessment by Target | 48 | 2 |
Assessment by Mechanism of Action | 50 | 2 |
Assessment by Route of Administration | 52 | 2 |
Assessment by Molecule Type | 54 | 2 |
Drug Profiles | 56 | 96 |
ACP-01 Drug Profile | 56 | 3 |
AEM-28 Drug Profile | 59 | 2 |
ALD-301 Drug Profile | 61 | 2 |
alprostadil Drug Profile | 63 | 1 |
Annexin A-5 Drug Profile | 64 | 1 |
apabetalone Drug Profile | 65 | 9 |
BAY-1193397 Drug Profile | 74 | 1 |
BC-1 Drug Profile | 75 | 1 |
beperminogene perplasmid Drug Profile | 76 | 6 |
CVBT-141C Drug Profile | 82 | 1 |
DVC-10101 Drug Profile | 83 | 1 |
ELS-140 Drug Profile | 84 | 1 |
JVS-100 Drug Profile | 85 | 5 |
levocarnitine propionate hydrochloride Drug Profile | 90 | 1 |
MGN-6114 Drug Profile | 91 | 1 |
MultiGeneAngio Drug Profile | 92 | 1 |
O-304 Drug Profile | 93 | 2 |
PC-mAb Drug Profile | 95 | 2 |
PDA-002 Drug Profile | 97 | 1 |
PF-05285401 Drug Profile | 98 | 10 |
REC-03 Drug Profile | 108 | 1 |
Rejuveinix Drug Profile | 109 | 1 |
rivaroxaban Drug Profile | 110 | 14 |
SB-030 Drug Profile | 124 | 2 |
sodium nitrite SR Drug Profile | 126 | 2 |
Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology Drug Profile | 128 | 6 |
transcrocetinate sodium Drug Profile | 134 | 4 |
TXA-127 Drug Profile | 138 | 3 |
V-10 Drug Profile | 141 | 1 |
VM-202 Drug Profile | 142 | 3 |
vonapanitase Drug Profile | 145 | 4 |
YY-984 Drug Profile | 149 | 1 |
zibotentan Drug Profile | 150 | 2 |
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Dormant Projects | 152 | 4 |
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Discontinued Products | 156 | 1 |
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Product Development Milestones | 157 | 10 |
Featured News &Press Releases | 157 | 1 |
Oct 25, 2016: Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference | 157 | 1 |
Oct 20, 2016: Dr. Jackie R. See M.D. Joins AngioSoma, Scientific Advisory Board | 157 | 1 |
Oct 20, 2016: Proteon Therapeutics Appoints Paul Hastings Chairman of Its Board of Directors | 158 | 1 |
Oct 11, 2016: AngioSoma Files 3 New Patent Applications on Liprostin | 158 | 1 |
Oct 03, 2016: Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada | 159 | 1 |
Sep 29, 2016: Low levels of endogenous anti-PC identified as a novel risk factor for vein bypass graft failure and cardiovascular complications in PAD patients | 159 | 1 |
Sep 28, 2016: Athera presents positive First-in-Patient data with their new antibody against immunovascular disease at ESVS | 160 | 1 |
Aug 11, 2016: Athera Biotechnologies completes First-in-Patient Study with New Antibody Against Immunovascular Disease | 160 | 1 |
May 24, 2016: Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis &Transplant Association Congress (ERA-EDTA) | 161 | 1 |
Apr 13, 2016: Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease | 162 | 1 |
Feb 04, 2016: Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease | 162 | 1 |
Oct 12, 2015: Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015 | 163 | 1 |
Aug 13, 2015: Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease | 164 | 1 |
Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor | 165 | 1 |
Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease | 165 | 2 |
Appendix | 167 | 2 |
Methodology | 167 | 1 |
Coverage | 167 | 1 |
Secondary Research | 167 | 1 |
Primary Research | 167 | 1 |
Expert Panel Validation | 167 | 1 |
Contact Us | 167 | 1 |
Disclaimer | 168 | 1 |